261, 262 Although high rates of efficacy were reported (47 to 64%), given the extremely small combined sample size of fewer than 30 patients, the relatively serious AEs (e.g., new diabetes onset, exacerbation of existing diabetes, pneumonia with septic shock, increased blood pressure), and the known risks of systemic long-term glucorticoid use, risks/burdens clearly outweigh benefits and the Panel recommends that this therapy not be used long-term
This simplicity appeals to people who dislike injections or want to minimize complexity in their protocol
Commonly reported observations include injection site reactions, mild gastrointestinal effects, and transient flushing
This may vary from twice weekly to once every 2-4 weeks (source: The basics of treatment It is not understood why certain patients require more frequent B12 treatment
Due to their small size, they tend to act faster and with more target specificity than large proteins or traditional hormones